Vectorite Biomedical (ROCO:4170) Research & Development: NT$15.48 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4170 Vectorite Biomedical Inc ROCO:4170
65 GF Score
Price NT$12.50
GF Value NT$17.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vectorite Biomedical Research & Development?

Vectorite Biomedical ROCO:4170 +0.81% 65 Research & Development is NT$15.48 Mil as of Dec. 2025. GuruFocus rates ROCO:4170 with a GF Score™ of 65/100 and a GF Value™ of NT$17.56 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vectorite Biomedical's Research & Development for the six months ended in Dec. 2025 was NT$7.48 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$15.48 Mil.

Vectorite Biomedical  (ROCO:4170) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vectorite Biomedical Research & Development Related Terms

Vectorite Biomedical Research & Development Historical Data

* Premium members only.

The historical data trend for Vectorite Biomedical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectorite Biomedical Research & Development Chart

Vectorite Biomedical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.25 5.43 6.59 16.96 15.48

Vectorite Biomedical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.18 6.96 10.00 7.99 7.48
ROCO:4170
65GF Score
Vectorite Biomedical Inc ROCO:4170
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectorite Biomedical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$15.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$15.48 Mil mean?
Vectorite Biomedical (ROCO:4170) has a Research & Development of NT$15.48 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vectorite Biomedical and its competitors.
Is Vectorite Biomedical's Research & Development too high?
Vectorite Biomedical's current Research & Development is NT$15.48 Mil. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Research & Development compare to VRTX and REGN?
Vectorite Biomedical's Research & Development of NT$15.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vectorite Biomedical and its competitors. Vectorite Biomedical's current Research & Development is NT$15.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.56, compared to a current price of NT$12.50 — trading 28.8% below its estimated fair value. The current Research & Development is NT$15.48 Mil. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Research & Development is NT$15.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?

Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued. The current stock price of NT$12.50 is trading 28.8% below its estimated GF Value™ of NT$17.56. GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.

Key valuation signals for ROCO:4170:

  • Research & Development: NT$15.48 Mil
  • GF Value™: NT$17.56 vs. price of NT$12.50 (28.8% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vectorite Biomedical Business Description

Address Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score

Get the complete analysis for ROCO:4170

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.50
Price
NT$17.56
GF Value